Key result
Supplemental oxygen inducing hyperoxia in normoxic cardiac patients decreases coronary blood flow by 15% to 29% and increases coronary vascular resistance by 20% to 41% without proven clinical benefit.
Why the study?
Supplemental oxygen is widely used in normoxic cardiac patients despite no randomized, blinded, controlled studies showing benefit and mounting evidence of potential adverse cardiovascular effects from hyperoxia.
Does supplemental oxygen therapy improve clinical or physiological outcomes compared to room air in normoxic patients with acute presentations of coronary artery disease?
Does supplemental oxygen therapy improve clinical or physiological outcomes compared to room air in normoxic patients with acute presentations of coronary artery disease?
Routine supplemental oxygen in normoxic patients with acute coronary syndromes lacks randomized trial support and induces hyperoxic coronary vasoconstriction, challenging guideline recommendations for its widespread use.
Answers are grounded in this paper and cite their sources.
May warrant caution with oxygen in normoxic ACS; leaves open optimal targets pending randomized outcome trials.
Over the past century, lacking the precision of today’s advanced technology, multiple studies provided conflicting data on the effects of oxygen therapy in normoxic cardiac patients. More importantly, no randomized, blinded and controlled studies have shown a benefit of such treatment. Yet the use of supplemental oxygen is widespread in cardiac patients. In these conditions, inadvertent hyperoxia commonly occurs because of concerns to ensure sufficient oxygenation and because hyperoxia is not perceived to be detrimental. In recent years, there has been mounting evidence demonstrating the potential adverse effects of hyperoxia on the cardiovascular system. In this report, we review data examining the effects of supplemental oxygen in normoxic patients with acute presentations of coronary artery disease (CAD). It is also the aim of this report to emphasize the point that oxygen therapy might have major adverse physiologic effects that must be considered when it is employed.
No takes yet. Share an insight, caveat, or question.
Moradkhan et al. (2010) conducted a review in Normoxic patients with acute presentations of coronary artery disease (CAD). Supplemental oxygen therapy (hyperoxia) vs. Room air / normoxia was evaluated on Coronary blood flow, coronary vascular resistance, and clinical outcomes in acute coronary syndrome. Supplemental oxygen inducing hyperoxia in normoxic cardiac patients decreases coronary blood flow by 15% to 29% and increases coronary vascular resistance by 20% to 41% without proven clinical benefit.
Synapse has enriched 10 related papers. Consider them for comparative context: